{
    "ticker": "AXSM",
    "name": "Axovant Gene Therapies Ltd.",
    "description": "Axovant Gene Therapies Ltd. is a clinical-stage gene therapy company focused on developing innovative treatments for neurological diseases. Founded in 2014, the company is committed to delivering transformative therapies aimed at addressing the unmet needs of patients with neurodegenerative diseases, particularly those affecting cognition and movement. Axovant's proprietary gene therapy platform leverages advanced technologies to deliver therapeutic genes to target areas of the central nervous system. The company\u2019s lead product candidates are designed to treat conditions such as Parkinson's disease and other cognitive disorders. Through rigorous scientific research and collaborations with leading academic institutions and research organizations, Axovant aims to advance its pipeline of therapies while ensuring the highest standards of safety and efficacy. The company is headquartered in Hamilton, Bermuda, and has a strong commitment to innovation, bringing together a diverse team of scientists and industry experts dedicated to improving the lives of patients suffering from debilitating neurological conditions. Axovant continues to pursue opportunities for growth through strategic partnerships and a focus on developing cutting-edge gene therapies that can make a meaningful difference in the field of neurology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Hamilton, Bermuda",
    "founded": "2014",
    "website": "https://www.axovant.com",
    "ceo": "David Hung",
    "social_media": {
        "twitter": "https://twitter.com/Axovant",
        "linkedin": "https://www.linkedin.com/company/axovant-gene-therapies"
    },
    "investor_relations": "https://investors.axovant.com",
    "key_executives": [
        {
            "name": "David Hung",
            "position": "CEO"
        },
        {
            "name": "Sanjay B. Bansal",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapies",
            "products": [
                "AXO-Lenti-PD",
                "AXO-AAV-GM1"
            ]
        }
    ],
    "seo": {
        "meta_title": "Axovant Gene Therapies Ltd. | Innovative Gene Therapies for Neurological Diseases",
        "meta_description": "Explore Axovant Gene Therapies Ltd., a leader in developing gene therapies for neurological diseases. Learn about our innovative treatments and commitment to patient care.",
        "keywords": [
            "Axovant",
            "Gene Therapy",
            "Neurological Diseases",
            "Biotechnology",
            "Pharmaceuticals",
            "Parkinson's Disease"
        ]
    },
    "faq": [
        {
            "question": "What does Axovant focus on?",
            "answer": "Axovant focuses on developing gene therapies for neurological diseases."
        },
        {
            "question": "Who is the CEO of Axovant?",
            "answer": "David Hung is the CEO of Axovant Gene Therapies Ltd."
        },
        {
            "question": "Where is Axovant headquartered?",
            "answer": "Axovant is headquartered in Hamilton, Bermuda."
        },
        {
            "question": "What are Axovant's main product candidates?",
            "answer": "Axovant's main product candidates include AXO-Lenti-PD and AXO-AAV-GM1."
        },
        {
            "question": "When was Axovant founded?",
            "answer": "Axovant was founded in 2014."
        }
    ],
    "competitors": [
        "AVXL",
        "CGEN",
        "RGEN",
        "ALNY"
    ],
    "related_stocks": [
        "BIIB",
        "VRTX",
        "REGN",
        "NVS"
    ]
}